Medtronic Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Medtronic Plc on June 22, 2022, regarding events occurring on that date and effective June 27, 2022. The filing pertains to corporate governance changes involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from 10 to 11 members.
- New Appointment: Lidia L. Fonseca was appointed as a new director, effective June 27, 2022.
- Committee Assignments: Ms. Fonseca was appointed to the Science and Technology committee and the Compensation committee.
- Compensation: Ms. Fonseca is eligible for an annual cash retainer and a director equity grant consistent with the Company's non-employee director compensation policy.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It confirms there were no undisclosed arrangements regarding Ms. Fonseca's selection and no reportable transactions involving her or her immediate family.
Key Facts for Investor Verification
- Verify the effective date of the new director's appointment (June 27, 2022).
- Review the attached press release (Exhibit 99.1) for additional biographical details on Lidia L. Fonseca.
- Confirm the specific compensation amounts by referencing the Definitive Proxy Statement on Schedule 14A filed on October 8, 2021.
- Note that this filing does not impact the company's financial statements or debt obligations.